Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice

Journal of Clinical Investigation

Volumn 105, Issue 11, 2000, Pages 1605-1612

  Daugherty, Alan ^a,b   Manning, Michael W ^b   Cassis, Lisa A ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; APOLIPOPROTEIN E;

ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; HYPERLIPIDEMIA; IMMUNOCYTOCHEMISTRY; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0034129997     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7818     Document Type: Article

References (63)

1. Alderman, M.H., et al. 1991. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N. Engl. J. Med. 324:1098-1104.
2. Pfeffer, M.A., et al. 1992. Effect of captropril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 327:669-677.
3. Samani, N.J., Thompson, J.R., O'Toole, L., Channer, K., and Woods, K.L. 1996. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 94:708-712.
4. Iwai, N., Inagami, T., Ohmichi, N., and Kinoshita, M. 1996. Renin is expressed in rat macrophage/monocyte cells. Hypertension. 27:399-403.
5. Diet, E. et al. 1996. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 94:2756-2767.
6. Potter, D.D., Sobey, C. G., Tompkins, P.K., Rossen, J.D., and Heistad, D.D. 1998. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 98:800-807.
7. Aberg, G., and Ferrer, P. 1990. Effects of captopril on artherosclerosis in cynomolgus monkeys J. Cardiovasc. Pharmacol. 15(Suppl.):S65-S72.
8. Charpiot, P., et al. 1993. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler. Thromb. 13:1125-1138.
9. Chobanian, A.V., Haudenschild, C.C., Nickerson, C., and Drago, K. 1990. Antiatherogenic effect of capropril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 15:327-331.
10. Campbell, J. H., Fennessy, P., and Campbell, G.R. 1992. Effect of perindopril on the development of atherosclerosis in the cholesterol-fed rabbit. Clin. Exp. Pharmacol. Physiol. 19:13-17.
11. Schuh, J.R., Blehm, D.J., Frierdich, G.E., McMahon, E.G., and Blaine, E.H. 1993. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J. Clin. Invest. 91:1453-1458.
12. Finta, K.M., et al. 1993 Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis. 100:149-156.
13. Hoshida, S., et al. 1997. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enapapril. Atherosclerosis. 130:53-59.
14. Kowala, M.C., et al. 1998. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril. J. Cardiovasc. Pharmacol. 32:29-38.
15. Kowala, M.C., Recce, R., Beyer, S., and Aberg, G. 1995. Regression of early atherosclerosis in hyperlipidemic hamsters induced by fosinopril and captopril. J. Cardiovasc. Pharmacol. 25:179-186.
16. Hayek, T., Attias, J., Smith, J., Breslow, J.L., and Keidar, S. 1998. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E deficient mice. J. Cardiovasc. Pharmacol. 31:540-544.
17. Fukamizu, A., et al. 1989. Tissue-specific expression of the human renin gene in transgenic mice. Biochem. Biophys. Res. Commun. 165:826-832.
18. Takahashi, S., et al. 1991. Expression of the human angiotensinogen gene in transgenic mice and transfected cells. Biochem. Biophys. Res. Commun. 180:1103-1109.
19. Sugiyama, F., et al. 1997. Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab. Invest. 76:835-842.
20. Chobanian, A.V., and Alexander, R.W. 1996. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch. Intern. Med. 156:1952-1956.
21. Kim, J.A., Berliner, J.A., and Nadler, J.L. 1996. Angiotensin II increases monocyte binding to endothelial cells. Biochem. Biophys. Res. Commun. 226:862-868.
22. Yanagitani, Y., et al. 1999. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension. 33:335-339.
23. Keidar, S. 1998. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci. 63:1-11.
24. Daugherty, A., and Roselaar, S.E. 1995. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovasc. Res. 29:297-311.
25. Cole, T.G., Kitchens, R., Daugherty, A., and Schonfeld, G. 1990. An improved method for separation of triglyceride-rich lipoproreins by FPLC. Pharmacia Biocommunique. 4:4-6.
26. Cassis, L.A., Marshall, D.E., Fettinger, M.J., Rosenbluth, B., and Lodder, R.A. 1998. Mechanisms contributing to angiotensin II regulation of body weight. Am. J. Physiol. 274:E867-E876.
27. Nakashima, Y., Plump, A.S., Raines, E.W., Breslow, J.L., and Ross, R. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:133-140.
28. Daugherty, A., et al. 1997. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/-mice. J. Clin. Invest. 100:1575-1580.
29. Zhang, S.H., Reddick, R.L., Piedrahita, J.A., and Maeda, N. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
30. Plump, A.S., et al. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein-E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
31. Oliverio, M.I., et al. 1997. Angiotensin II responses in AT1a receptor-deficient mice: a role for AT1b receptors in blood pressure regulation. Am. J. Physiol. 272:F515-F520.
32. Shesely, E.G., et al. 1996. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 93:13176-13181.
33. Johns, C., Gavras, I., Handy, D.E., Salomao, A., and Gavras, H. 1996. Models of experimental hypertension in mice. Hypertension 28:1064-1069.
34. Davis, W.M., and King, W.T. 1967. Pharmacogenetic factor in the convulsive responses of mice to flurothyl. Experientia. 23:214-215.
35. Davisson, R.L., et al. 1997. Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes. J. Clin. Invest. 99:1258-1264.
36. Bertaux, F., et al. 1997. Normotensive blood pressure in mice with a disrupted renin Ren-1d gene. Transgenic Res. 6:191-196.
37. Bing, J., and Poulsen, K. 1979. In mice aggressive behavior provokes vast increase in plasma renin concentration, causing only slight, if any, increase in blood pressure. Acta Physiol. Scand. 105:64-72.
38. Wang, D.H., Du, Y., and Yao, A. 1996. Regulation of the gene-encoding angiotensin II receptor in vascular tissue. Microcirculation. 3:237-239.
39. Su, E.J., Lombardi, D.M., Siegal, J., and Schwartz, S.M. 1998. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension. 31:1331-1337.
40. Jardine, A.G. 1995. Angiotensin II and glomerulonephritis. J. Hypertens. 13:487-493.
41. Daugherty, A. 1997. Lymphocytes in atherosclerotic lesions: bystanders or active participants. Atherosclerosis ID Research Alert. 9:395-400.
42. Stemme, S., and Hansson, G.K. 1994. Immune mechanism in arherosclerosis. Coron. Artery Dis. 5:216-222.
43. Roselaar, S.H., Kakkanathu, P.X., and Daugherty, A. 1996. Lymphocyte populations in atherosclerotic lesions of ApoE-/-and LDL receptor -/-mice: decreasing density with disease progression. Arteriosder. Thromb. Vasc. Biol. 16:1013-1018.
44. Traub, O., and Berk, B.C. 1998. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler. Thromb. Vasc. Biol. 18:677-685.
45. Hahn, A.W., Jonas, U., Buhler, F.R., and Resink, T.J. 1994. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 347:178-180.
46. Chen, X.L., Tummala, P.E., Olbrych, M.T., Alexander, R.W., and Medford, R.M. 1998. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ. Res. 83:952-959.
47. Hernandez-Presa, M., et al. 1997. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 95:1532-1541.
48. Boring, L., et al. 1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100:2552-2561.
49. Carr, M.W., Roth, S.J., Luther, E., Rose, S.S., and Springer, T.A. 1994. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA. 91:3652-3656.
50. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801-809.
51. Ylä-Herttuala, S., et al. 1991. Expression of monocyte chemoattractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 88:5252-5256.
52. Gu, L., et al. 1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2:275-281.
53. Gosling, J., et al. 1999. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103:773-778.
54. Boring, L., Gosling, J., Cleary, M., and Charo, I.F. 1998. Decreased lesion formation in CCR2(-/-) mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894-897.
55. Kranzhofer, R., Browatzki, M., Schmidt, J., and Kubler, W. 1999. Angiotensin II activates the proinflammatory transcription factor nuclear factor-B in human monocytes. Biochem. Biophys. Res. Comm. 257:826-828.
56. Carrell, T.W., Smith, A., and Burnand, K.G. 1999. Experimental techniques and models in the study of the development and treatment of abdominal aortic aneurysm. Br. J. Surg. 86:305-312.
57. Tangirala, R.K., Rubin, E.M., and Palinski, W. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36:2320-2328.
58. Carmeliet, P., et al. 1997. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17:439-444.
59. Nishijo, N., et al. 1998. Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II. Lab. Invest. 78:1059-1066.
60. Takenaka, K., et al. 1998. Angiotensin I-converting enzyme gene polymorphism in intracranial saccular aneurysm individuals. Neurol. Res. 20:607-611.
61. Huang, W., Alhenc Gelas, F., and Osborne-Pellegrin, M.J. 1998. Protection of the arterial internal elastic lamina by inhibition of the renin-angiotensin system in the rat. Circ. Res. 82:879-890.
62. Mahley, R.W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:622-630.
63. Daughtery, A., and Cassis, L.A. 1999. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/-mice. Ann. NY Acad. Sci. 892:108-118.